INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune disease characterised by autoimmunity, vasculopathy, inflammation and fibrosis. 1 The disease is highly heterogeneous and can be broadly classified into two subtypes of SSc depending on the degree of skin involvement. Diffuse SSc is classified when there is generalised fibrosis of the skin, and limited SSc when there is little fibrosis of the skin. Raynaud's phenomenon appears for years before fibrosis is clearly present. Fibrosis is due to an accumulation of extracellular matrix (ECM) that ultimately impairs organ function. Diffuse SSc appears to be more aggressive with a poorer prognosis. That inflammation and vascular damage precedes fibrosis indicates that they have a role in fibrogenesis. 2 Genetic data reveal that the role of genetics in SSc appears relatively small; however, epigenetics could possibly have a much larger role. Epigenetics is the study of heritable changes in gene expression that are not due to changes in DNA sequence. The changes are stable and inherited but do not involve mutations of the DNA itself. Epigenetic processes are many and varied and include DNA methylation, histone modifications and microRNAs (miRs) Figure 1 ; importantly, there is cross-talk between the three. Heritable changes not due to alterations in DNA sequences may underlie some of the pathogenetic pathways of SSc disease and in particular may underlie the observed autocrine alterations found in diseased fibroblasts from SSc patients after skin biopsies. Here, the 'renegade' cells are autonomous and this can be perpetuated in in vitro culture over multiple passages where they secrete high levels of matrix molecules and retain a myofibroblast phenotype. Unrestrained excessive synthesis and secretion of collagen by activated resident fibroblasts is the hallmark of the disease leading to thickening of the affected region. Epigenetics is a key adaptive mechanism via environmental exposure that can induce lasting changes in gene expression and thus impact the function of the cell. The epigenome of the cells involved in SSc may have a pivotal role in disease pathogenesis and is altered by the environment. Emerging evidence suggests that aberrant epigenetic mechanisms are involved in SSc development. The aim of this review is to examine the role(s) of epigenetics in SSc pathogenesis owing to a rapid gain in recent knowledge.
MIRS
MiRs are small, non-coding RNAs, around 21 nucleotides in length, that mediate messenger (mRNA) cleavage, translational repression or mRNA destabilisation via partial complementary binding to the 3 0 -untranslated region (UTR) in target transcripts. Thus, they are regulators of gene expression. It is now known that there are over 1500 identified miRs, and each of them targets hundreds of genes and is expressed in a tissue and cell type-specific manner. 3 Because miRs have a modest effect on gene expression they are termed 'fine tuners' of gene expression and often target mRNAs governing the same biological process or pathway. They were discovered in 1993 using the nematode worm Caenorhabditis elegans through characterisation of genes that control timings of larval development. The RNA was called lin-4 and was found to negatively regulate the expression of a protein LIN-14. 4 This was found in part through sequence complementarity between lin-4 and unique repeats within the 3 0 -UTR of the LIN-14 mRNA. The reduction via this mechanism of repression of LIN-14 initiates the developmental progression into the second larval stage. Seven years later, let-7 was discovered in C elegans and this miR was found to also regulate essential stages in development in this worm. 5 Soon after, it was discovered that let-7 was in the human genome and is highly conserved, and many other miRs were subsequently discovered. It is now known that there are hundreds of miRs in the human genome. In fact, miRs account for around 1-2% of the human genome. miRs are first transcribed by RNA polymerase II as pri-miRNA, then cleaved by the RNAse III enzyme Drosha and DGCR-8 6 to pre-miRs, and these are then exported to the cytoplasm and further cleaved by Dicer to form a miR duplex of B21 nucleotides in length. This then enters the RNAinduced silencing complex and finally forms mature miR. 7 When
Dicer cleaves the pre-miR stem loop, two complementary short RNA molecules are formed, but only one is integrated into the RNA-induced silencing complex. This mature miR can then mediate mRNA target cleavage, translational repression or mRNA deadenylation. Each miR likely targets hundreds of distinct mRNAs, thus adding a layer of complexity to gene regulation. By exerting control over the expression of their target proteins in cells, they have emerged as key regulators of many processes through targeting of a single or related pathway. SSc is a complex disease whose underlying molecular mechanisms are poorly characterised. Despite intense research efforts in dissecting the disease, many aspects of the pathogenesis remain incompletely understood. In terms of genetics the role of inheritance is small; however, it is likely that epigenetics has a role, and differentially expressed miRs have been identified in SSc. It is interesting that certain miRs target one facet of the diseasethat is, inflammation-whereas others target the fibrosis. In particular, one miR, miR29a, has been identified as being downregulated in SSc fibroblasts and also in skin biopsies concurrent with elevated collagen 1A1 levels. 8 Enforced overexpression of miR29 in diseased SSc dermal fibroblasts reduced collagen 1 and 3 levels in these fibroblasts, and confirmation of collagen3A1 as a direct bona fide target was made using HEK luciferase reporter lines. The bleomycin model of fibrosis is an inflammation-dependant model of SSc that needs multiple lymphocyte and cytokines to mimic the disease pathogenesis. This is a useful model for dissecting the disease. Using this model, Maurer et al. 8 found reduced levels of miR29 similar to the human and in vitro situation. Interestingly, this could be reversed by both in vitro treatment and in the bleomycin animal model using the tyrosine kinase inhibitor imatinib. This suggests that the mechanism of action, at least partly, of imatinib is to increase reduced levels of miR29, thus mediating suppression of collagen expression. It is of interest that transforming growth factor beta (TGF-b) can also decrease miR29a, 9 as TGF-b is a key cytokine in mediating fibrosis. We have also found reduced levels of miR29a in dermal fibroblasts from SSc donors (Figure 2 ). In vivo sleeping-beauty miR29 gene-mediated transfer prevented and treated bleomycin-induced pulmonary fibrosis. 10 Interestingly, lower amounts of miR29a have been demonstrated in serum from patients with 'scleroderma spectrum disorder'. 11 We have also identified a new definite target of miR29a that mediates fibrosis via direct targeting of a pro-fibrotic molecule leading to fibrosis. 12 It has also been shown in the bleomycin model of fibrosis that miR155 is elevated and that this targets the keratinocyte growth factor, a growth factor implicated in fibrosis. 13 Serum miR142-3p was found to be elevated in SSc patients compared with controls; however, no target gene was ascertained in this study.
14 It should also be pointed out that an 'endogenous housekeeper' is not universally accepted and many people use let-7 as a 'housekeeper' miR; however, the levels of the miR can also change depending on the disease context. Thus, it is suggested that arrays are performed to confirm a stable 'housekeeping' miR in each study. A specific polymorphism in miR146a is associated with telangiectasia in SSc. 15 It has also been recently demonstrated that miR92a levels in serum are elevated in SSc compared with controls, but not serum miR135. In vitro fibroblasts from patients also demonstrated elevated levels of Figure 1 . Mechanisms of epigenetics. Schematic of the epigenetic modulations represented by histone modification, DNA methylation and RNA interference. Histone modification is reversible and site-specific. Histone alteration via acetylation, methylation, phosphorylation, ubiquitination, sumoylation. DNA methylation refers to covalent addition of a methyl group to the 5 0 -position of the cytosine ring via DNA methyltransferase (DNMT). RNA interference is formation of miR-mRNA duplexes leading to mRNA degradation or translational repression and consequently gene silencing. Figure 2 . Reduced miR29a levels in SSc. Dermal fibroblast were cultured from SSc patients or healthy controls and quantitative PCR was performed for miR29a and small nucleolar RNA (SNORD) using Taqman probes. Data were normalised to SNORD.
Epigenetics in systemic sclerosis M Ciechomska et al miR92a and that this miR could be attenuated by small interfering RNA (siRNA) transfection of TGF-b, suggesting that TGF-b regulates miR92a expression. In addition, forced overexpression of miR92a in dermal fibroblasts reduced matrix metalloproteinase-1 (MMP-1) levels. The authors suggest that this is a bona fide target of miR92a, but they did not confirm this with luciferase reporter assays with the 3 0 -UTR of MMP-1. 16 It has also been reported that miR196a levels are lower (nonsignificant) in SSc compared with control sera, and this significantly correlated with diffuse SSc and also with the modified Rodnan skin score, suggesting a possible biomarker. 17 Further, they also found lower levels of miR196a in SSc dermal fibroblasts and normal fibroblasts stimulated with TGFb. It was also demonstrated that miR196a regulates collagen, either directly or indirectly, as an inhibitor of miR196a leads to the overexpression of collagen1 and as overexpression of miR192a by transfection in SSc fibroblasts attenuates collagen levels. It also appears that collagen is a bona fide direct target of miR196a. As the group did not use reporter assays, they used an miR target protection assay to inhibit interaction with the miR and mRNA of the gene target and they found elevation of collagen levels, suggesting that this is a direct mRNA target of the miR. It has also been demonstrated that SSc fibroblasts have elevated levels of miR7, which was confirmed by in situ hybridisation, and that this miR7 is regulated by the matricellular protein Thrombospondin 2.
18 Thrombospondin 2 is a large glycoprotein involved in cellmatrix interactions. 19 However, another paper has found significantly decreased levels of miR7 in localised scleroderma patients' serum versus healthy control serum, but no difference in miR29a in the same samples. This group also demonstrated in tissue that the miR7 levels are decreased in localised scleroderma and also in keloid tissue, both by quantitative PCR and in situ hybridisation in tissue. 20 Furthermore, the authors also showed that collagena2I is a direct target gene of miR7. Recent evidence has pointed to the role of miR150 as a pathological mediator in SSc. Honda et al. 21 found that serum levels of miR150 were decreased in SSc patients as compared with controls and that these patients tended to have more severe clinical manifestations. Examining this further they also found decreased miR150 both in the tissue in situ using in situ hybridisation and also in isolated dermal fibroblasts. Furthermore, the actual target of miR150 in these cells was found to be integrin b3. Thus, miR150 targets integrin b3, thus reducing fibrosis via downregulation of collagen. Integrins are cell surface glycoproteins involved in a variety of different cellular functions, including proliferation, adhesion and cell attachment to ECM. Integrins function as heterodimers comprising an a-and b-chain. Quite how miR150-mediated integrin b3 activation leads to elevated collagen synthesis is unknown; however, one can speculate given the known role of integrins in the activation of latent TGF-b that the effect is mediated by facilitating the activation of latent TGF-b and that this would lead to increased collagen synthesis. Table 1 illustrates differentially expressed miRs in SSc and targets if identified.
Because one miR is predicted to target many hundreds of mRNAs and one gene can be regulated by many miRs, the level of fine-tuning of gene expression is huge. 3 However, each target of an miR needs to be experimentally validated and target prediction programmes are not always accurate.
DNA METHYLATION
Another epigenetic phenomenon is DNA methylation: methylation of cytosine at position C5 at CpG dinucleotides. CpG islands are stretches of DNA located mainly in promoter regions; therefore, methylation of such CpG islands in promoter regions regulates gene transcription and is the most widely studied epigenetic programming. Methylation of CpGs leads to gene repression by inhibiting the binding to transcription factors. Maintenance of DNA methylation when the cell divides is mediated by the enzyme DNA methyltransferase-1 (DNMT-1), which copies the DNA 'signature' to the synthesised strand. 22 DNMT-3A and DNMT-3B are de novo methyltransferases; deletion of either enzyme in mice is embryonically lethal. 23 Methylation abnormalities have been associated with many diseases, most notably cancer, where aberrant methylation allows certain genes to be expressed to allow cells to become malignant. DNA methylation causes transcriptional silencing 22 and is critical in gene regulation. It has also been shown that rheumatoid arthritis synovial fibroblasts both in the tissue (in situ) and in vitro from rheumatoid arthritis patients are globally hypomethylated, and normal synovial fibroblasts treated with 5-aza-2 0 -deoxycytidine (5-aza-C) to induce hypomethylation resulted in elevated proteins involved in disease pathogenesis, such as CD10, CD130 and MMP-14, 24 and may be modulated by the local microenvironment. Interestingly, methylation itself has been shown to alter miR levels in rheumatoid arthritis, 25 showing intricate cross-regulation. Hypermethylation of RASAL1 promoter, encoding an inhibitor of the Ras oncoprotein, has been associated with kidney fibrosis and the maintenance of a fibrotic phenotype via myofibroblast activation. 26 Further, aberrant DNA methylation has been observed in idiopathic pulmonary fibrosis. 27 A recent genomewide methylation study in SSc from dermal fibroblasts was undertaken and demonstrated differentially methylated loci in thousands of sites and this included hypomethylation of ITGA9, an integrin. 28 SSc is an autoimmune disease in which T cells have a critical role, 2 especially early in the disease process, when they are found in the skin. These T cells likely have a role by engaging cognate antigens presented to them by resident antigen-presenting cells and then secreting cytokines that propagate fibrosis by resident stromal cells. 29 It has now been demonstrated that CD4 þ helper T cells display global DNA hypomethylation in SSc patients (similar to SLE) compared with control T cells. Furthermore, the levels of the DNA methyltransferases mRNA transcripts were significantly reduced in the SSc group compared with control, suggesting an underlying mechanism for the hypomethylation found in the T cells. 30 However, this was a 'global' DNA hypomethyation and gave no indication of which CD4 T-cell gene promoter regions are unmethylated, leading to aberrant gene expression of cytokines. Alterations in DNMT levels would affect methylation patterns and thus this would be interesting to examine in SSc. Demethylation of the CD40 ligand (CD40L) in regulatory regions of the inactive X chromosome has been demonstrated to contribute to CD40L overexpression in CD4 þ T cell in female patients with SSc. 31 This suggested that hypomethylation leads to reactivation of the silent X chromosome and thus to increased CD40L expression on CD4 þ T cells, and that this elevated T-cell protein has a role in fibrosis through the promotion of interactions with fibroblasts altering ECM deposition. In a similar study, the same group found hypomethylation of the CD70 promoter region in CD4 þ T cells from SSc patients compared with controls and also elevated levels Abbreviations: miRs, microRNAs; SSc, systemic sclerosis.
Epigenetics in systemic sclerosis M Ciechomska et al
of CD70 on the cells, and an inverse relationship was apparent between the variables. 32 CD70 is part of the tumour necrosis factor superfamily and is restricted to T and B lymphocytes and mature dendritic cells and is an important checkpoint in the regulation of immunity and is needed for co-stimulation. It is also found to be elevated in rheumatoid arthritis T cells and chronically activated T cells from other disease entities. Differential methylation patterns on the X chromosome in monozygotic twin subjects with SSc have been described in the literature. 33 Dees et al. 34 demonstrated promoter hypermethylation of the endogenous Wnt antagonists Dickkopf-1 and secreted frizzledrelated protein-1 in dermal fibroblasts; this leads to reduced levels of the antagonists enabling enhanced Wnt signalling. Enhanced Wnt signalling is a primary pro-fibrotic pathway in SSc. 35 Interestingly, reactivation of Wnt antagonists by the addition of 5-aza 0 c and thus demethylation of the promoter reversed the fibrotic effects both in in vitro dermal fibroblasts and in the bleomycin model of skin fibrosis, suggesting that 'erasure' of methylation could be a possible treatment via restoration of Wnt antagonists. 5-aza 0 c is a nucleoside analogue that is currently used to treat myelodysplastic syndromes.
Epigenetic repression of the friend leukaemia integration 1 transcription factor (Fli1) gene has been demonstrated in SSc dermal fibroblasts. 36 Fli1 is a transcription factor containing an ETS DNA-binding domain. Increased methylation of the Fli1 promoter was shown in SSc fibroblasts in vitro, and genomic DNA from fresh punch biopsies from SSc patients also showed higher methylation in the Fli1 promoter region; also introduction of an Fli1 antisense construct plasmid into cells to reduce Fli1 levels resulted in elevated collagen I protein levels, suggesting that Fli1 is a negative regulator of ECM expression. Therefore, a reduction in Fli1 levels through methylation in the promoter region of the gene leading to suppression of Fli1 results in excessive collagen synthesis. Intriguingly, ciprofloxacin, an antibiotic, has recently been shown to reduce collagen I at the transcriptional and protein levels. In SSc fibroblasts, elevated Fli1 levels mediated through a reduction in DNMT-1 levels and a concomitant increase in MMP-1 expression facilitates ECM deposition. This raises the possibility of an antibiotic treatment for the disease. Methyl CpG-binding protein 2, a protein that binds preferentially to methylated DNA and aids transcription through repression or activation, is important in regulating myofibroblast activation. Interestingly, hypoxia, which is prevalent in SSc patients, induced pro-fibrotic transformation via hypermethylation and DMNT-1 expression, mediated via hypoxia inducible factor-1a, a central transcription factor, in cardiac fibroblasts, leading to release of copious amounts of ECM. 37 It is known that hypoxia is commonplace in SSc and that hypoxia inducible factor-1a is overexpressed, mediated by reactive oxygen species. Deletion of hypoxia inducible factor-1a modulated the epigenetic-mediated myofibroblast activation. Thus, targeting DNMT expression may be a therapeutic option.
HISTONE MODIFICATIONS
DNA in cells is not naked but is tightly wrapped around histone proteins forming chromatin. Histones are subject to a wide variety of post-translational modifications including, but not limited to, lysine acetylation, lysine and arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination and sumoylation. Histone modifications affect chromosome function through two mechanisms: first, by altering the electrostatic charge of the histone and thus resulting in a conformational change; second, the modifications are protein-binding sites for protein recognition modules. One histone can carry multiple histone modifications and these can influence each other; the transcriptional activity of a gene is determined by the cumulative histone code. Histone acetylation works by opening chromatin and allowing transcription factors to gain access to the DNA template. Deacetylation results in the chromatin being in a bound closed state and is therefore transcriptionally silent. Histone acetylation is associated with actively transcribed chromatin. Acetylation and deacetylation are mediated by two antagonising enzymes: histone acetyltransferases and histone deacetylases (HDACs). HDAC inhibitors have been useful in animal models of antigen-induced arthritis and are being suggested as anticancer agents through anti-inflammatory and anti-proliferative mechanisms. 38, 39 Trichostatin A (TSA) is an HDAC inhibitor that inhibits class I and II, but not class III, HDACs: sirtuins. Skin fibroblasts treated with 100 nM of TSA resulted in inhibition of a-smooth muscle and collagen I mRNA levels and de novo protein synthesis; TSA also blocked the stimulatory effects of TGF-b on the expression of procollagen-a1 transcripts, suggesting an epigenetic mechanism. 40 TSA also blocked the differentiation of Rat hepatic stellate cell myofibroblasts, the cells responsible for hepatic fibrosis, by blocking the a-Sma and collagen synthesis at transcriptional and post-transcriptional levels. It was subsequently shown that the addition of TSA to skin fibroblasts caused significant inhibition of TGF-b-induced collagen I synthesis. This inhibition was not due to alterations in the Smad3 downstream signalling pathway, as Smad signalling components were unaltered, but rather due to the downregulation of Sp1; overexpression of Sp1 rescues TGF-binduced collagen1A2 promoter activity while incubated with TSA, thus showing that Sp1 is the mediating transcription. 41 In SSc fibroblasts, incubation of dermal fibroblasts with TSA reduced basal and cytokine (IL-4, TGF-b and PDGF)-induced increases in collagen I secretion in culture. 42 The mechanism of the TSAinduced reduction of cytokine-stimulated collagen I was through inhibition of Smad3/4 DNA-binding complexes; these are necessary to initiate collagen gene transcription downstream of cytokine ligation. Nuclear translocation of the transcription factors Smad3/4 was also inhibited by incubation with TSA. Furthermore, this was also applied to the bleomycin model of fibrosis, and application of a small amount of TSA resulted in a reduction in skin thickness in this model of fibrosis and a reduction in the bleomycin-induced increases and accumulation of ECM and collagen fibre bundles in the skin tissue. TSA is regarded as a general non-specific HDAC inhibitor, but incubating diseased SSc dermal fibroblasts revealed that HDAC7 was strongly downregulated after TSA treatment and yet HDAC3 was upregulated, suggesting differential effects. 43 siRNA against HDAC7 resulted in reduction in HDAC7 protein levels in dermal fibroblasts but no effect on HDAC3 levels, and siRNA-mediated reduction of HDAC7 results in abrogation of collagen levels, both constitutive and cytokine-stimulated (TGF-b) collagen increases. Moreover, HDAC7 silencing using specific siRNA did not alter the levels of PDGF-B or its cognate receptor (PDGF-Rb). The effect on fibronectin was different from TSA, and interestingly, TSA, but not silencing of HDAC7, induced upregulation of connective tissue growth factor (CTGF) and ICAM-1, both pro-fibrotic molecules, suggesting that HDAC7 silencing was more targeted than TSA as it does not induce the upregulation of more pro-fibrotic molecules. Recently it was shown that trimethylation on histone H3 on lysine 27 (H3K27me3) results in negative regulation of fibrosis. 44 Treatment of the bleomycin mouse model of fibrosis with 3-deazaneplanocin A (DZnep), an inhibitor of trimethylation of lysine 27 H3 (H3K27me3), results in exacerbations of fibrotic disease both in the bleomycin model and in the constitutively active TGF-bR1 receptor model of SSc. The mechanism appears to be the upregulation of the AP-1 family transcription factor Fos-related antigen-2 (FRA-2), as siRNA 'knockdown' of Fra-2 completely attenuates the pro-fibrotic effects of inhibition of H3K27me3. FRA-2 is an important transcription factor family member of the AP-1 family, which is important in mediating profibrotic effects. Also in idiopathic pulmonary fibrosis, fibroblasts treated with suberoylanilide hydroxamic acid, a clinical HDAC inhibitor, reduced their transdifferentiation into myofibroblasts and reduced collagen expression. Pharmacological targeting of HDACs appears a possible therapeutic in SSc, and various HDAC inhibitors are in clinical trials for other indications (Table 2) . It is of interest that many of the HDAC inhibitors are already approved and generally well tolerated.
LONG NON-CODING RNAS
Long non-coding RNAs (lnRNA) are longer versions of non-coding RNA (4200 nts) that appear to be extremely abundant and certainly affect gene expression. Indeed, eukaytotic genomes transcribe up to 90% of genomic DNA; yet only 1-2% encode for proteins. LnRNAs have an important function in chromatin and in altering DNA binding, and these functions may be subverted in SSc. Although to date no studies have been published on the expression of long non-codes in SSc, in a model of kidney fibrosis induced by urethral obstruction Smad-3-mediated fibrosis demonstrated two differentially expressed lnRNAs, including np5318. 45 Furthermore, differentially expressed lnRNAs have been recently demonstrated in pulmonary fibrosis. 46 There is a growing appreciation that these lnRNAs are extremely important in regulating gene expression and are perturbed in disease, and intense research efforts are underway. It is likely that miRs target lnRNAs for repression, and thus there is an interconnected network adding to the complexity of regulation.
CONCLUSION
SSc is a complex autoimmune disorder with a variety of manifestations, and epigenetic factors may have a key role in disease pathogenesis. The three main epigenetic modifications, miRNA, DNA methylation and histone modifiers, all have roles in SSc pathogenesis. The relative contribution of each distinct modification is, to date, unknown. However, although evidence for differentially expressed miRs has been found delineating, determination of the targets of such miRs is a more challenging process as each target has to be experimentally validated. It would be interesting to see whether different miRs direct the different aspects of the disease, such as the vascular abnormalities, the inflammation component and the fibrotic aspect. MiR29 has been shown to be a promising target in the disease not least because its bona fide target gene has been identified as collagen, the main ECM protein excessively produced in SSc. Thus, molecules that help restore appropriate levels of miR29 would reduce elevated levels of collagen in SSc. It is interesting to note that the locked nucleic acid-modified antagomiR to miR122, Miravirsen, targeting the liver-specific miR122, has produced excellent results in hepatitis C virus RNA reductions with no serious adverse effects. 47 This is the first antagomiR to be used in phase II clinical trials. Thus, the concept of targeting specific miRs in vivo is possible, especially using the locked nucleic acid technology. Likewise, compounds that alter DNA methylation levels would also be a good epigenetic modifier to alter the expression of Fli1, now known to be a repressor of ECM. The fluoroquinolone antibiotic ciprofloxacin is one such compound that modifies Fli1 by modulating DNMT-1 expression. Finally, the most promising of compounds appears to be TSA, a broad-spectrum histone deacetylase inhibitor that modulates histone acetylation and is a promising drug in cancer. In SSc it modulates a-smooth muscle actin expression and collagen deposition and is effective in animal models of SSc. 42 However, it is suggested that inhibition of HDAC7, using siRNA technology, may represent a more targeted approach and yields less 'off target' effects. 43 TSA may have too many unwanted side effects. However, using entinostat it was shown in a mouse model of fibrosis that reductions in renal fibrosis occurred that were mediated through repression of TGF-b signalling, yielding benefit. 48 Regression of fibrosis can occur in animal models and this may be associated with inherited epigenetic changes. 49 Furthermore, serum-derived miRs may serve as useful biomarkers to predict response to therapeutic treatment or stratification of patients as they are highly stable in sera. Future studies should be addressed to assess the validity of serum miR 'signature' in SSc as a non-invasive biomarker.
SSc is notoriously heterogeneous and the heterogeneity that underpins the disease may be attributed to epigenetic factors due to environmental or hormonal exposures. Because the epigenome is plastic and highly malleable, by factors such as diet, it is an attractive therapeutic target in a disease for which there are no therapies. Novel insight into the disease pathogenesis is aided by new technologies to interrogate the epigenome with deep sequencing and will likely reveal novel associations. However, as 
